CLOs on the Move

Senti Bio

www.sentibio.com

 
Our mission is to create a new generation of smarter medicines that outmaneuver complex diseases in ways previously inconceivable. To accomplish this mission, we are building a synthetic biology platform that could enable us to program next-generation cell and gene therapies with what we refer to as “gene circuits”. These gene circuits, which are created from novel and proprietary combinations of DNA sequences, are intended to reprogram cells with biological logic to sense inputs, compute decisions and respond to their cellular environments. We are designing gene circuits to improve the “intelligence” of cell and gene therapies in order to enhance ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.sentibio.com
  • 2 Corporate Drive First Floor
    South San Francisco, CA USA 94080
  • Phone: 510.520.8691

Executives

Name Title Contact Details

Similar Companies

Strides Inc

Strides Inc is a Somerset, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Green Point Research

Working to cultivate a better tomorrow by bringing together human, natural & financial resources to grow our businesses and communities.

Woodside Senior Communities

Woodside Senior Communities is a Green Bay, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Regenesis Biomedical

Regenesis Biomedical is a Scottsdale, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Insitro

insitro is a data-driven drug discovery and development company that leverages machine learning and high-throughput biology to transform the way medicines are created to help patients. At insitro, we are rethinking the entire drug discovery process, from the perspective of machine learning, human genetics, and high-throughput, quantitative biology. Over the past five decades, we have seen the development of new medicines becoming increasingly more difficult and expensive, leaving many patients with significant unmet need. We`re embarking on a new approach to drug development – one that leverages machine learning and unique in vitro strategies for modeling disease state and designing new therapeutic interventions. We aim to eliminate key bottlenecks in traditional drug discovery, so we can help more people sooner and at a much lower cost to the patient and the healthcare industry. We believe that by harnessing the power of technology to interrogate and measure human biology, we can have a major impact on many diseases. We invest heavily in cutting edge bioengineering technologies to enable the construction of large-scale, high-quality data sets that are designed specifically to drive machine learning methods. Our first application is to use human genetics, functional genomics, and machine learning to build a new generation of in vitro human cell-derived disease models whose response to perturbation is designed to be predictive of human clinical outcomes.